The effects of the calcium antagonists diltiazem and nicardipine on portal pressure and splanchnic blood flow were studied in awake, unrestrained portal hypertensive rats. Portal hypertension was induced in rats by partial portal vein ligation. Hemodynamic measurements were done using the radiolabeled microsphere technique. In portal veinligated and sham-operated rats, intraarterial diltiazem and nicardipine reduced mean arterial pressure. No significant changes, however, were observed in portal pressure and cardiac index. In portal vein-ligated rats, diltiazem and nicardipine increased portal tributary blood flow. Portal tributary vascular resistance was also significantly decreased. The decrease in the hepatocollateral vascular resistance prevented an increase in portal pressure. In sham-operated rats, these changes were not observed. It is possible that the vascular responses to calcium antagonists are altered in portal vein-ligated rats. These findings demonstrate that the hemodynamic effects of calcium antagonists occur at two levels. First, the increase in portal tributary blood flow appears to be a selective effect on portal tributary vascular resistance. Secondly, the portal pressure does not increase in parallel with the increase in portal tributary blood flow because of a similar reduction in portocollateral vascular resistance.
Introduction
Control of esophageal variceal bleeding secondary to portal hypertension remains a therapeutic challenge3 ,2
Offprint requests to: T. Kawasaki (Received Apr. 10, 1995; accepted Sept. 22, 1995) The pressure gradient (6p) across an organ is the product of flow (Q) and resistance (R). An increase in portal pressure can therefore result from an increase in flow and/or resistance? ,4 Since hepatic function is dependent upon adequate blood flow, the maintenance of hepatic perfusion should be a major therapeutic goal in the treatment of portal hypertension. Portal pressure should be lowered by a reduction in portal vascular resistance rather than by a reduction in hepatic blood flow. Several compounds including central (*2-agonists, 5 organic nitrates, 6 and serotonin-2-antagonists 7 have been shown to reduce splanchnic vascular resistance. Calcium antagonists have been shown to reduce systemic arterial pressure in in vivo experiments, and recently they have often been used in patients with liver cirrhosis suffering from hypertension. The effect of calcium antagonists on the portal circulation, however, is not well known. One calcium antagonist, verapamil, has been reported to reduce hepatic vascular resistance in rats with cirrhosis s and portal pressure in patients with cirrhosis. 9,~~ Two other calcium antagonists, diltiazem and nicardipine, are more potent vasodilators than verapamil. It was therefore of interest to investigate the effects of these two drugs on splanchnic hemodynamics in rats with portal hypertension induced by partial portal vein ligation 1~ to assess their efficacy in the treatment of portal hypertension.
Methods

Animals
Adult male Sprague-Dawley rats (Shizuoka Laboratory Animal Center, Shizuoka, Japan) weighing between 170 and 190g were used. All animals received humane care in compliance with the National Research Council criteria for humane care. Portal hypertension was induced by partial portal vein stenosis as previously described. 12,13 Briefly, under ether anesthesia, the portal vein was exposed through a median laparotomy. A 21-gauge blunt-tipped needle was placed along the length of the portal vein, and 4-0 silk was used to ligate both the needle arid the portal vein. The needle was then removed and the abdomen closed with catgut. In the sham-operated control rats, the portal vein was exposed but no needle or ligature was placed about the portal vein. Two weeks after ligation, the hemodynamic studies were conducted.
Portal pressure measurement
Following an overnight fast with free access to water, the rats were anesthetized with ether and the abdomen was opened. For portal pressure (PP) measurement, a PE-50 catheter (Intramedic PE-50, Becton-Dickinson, San Jose, CA, USA) was advanced into the lumen of the portal vein via the junction of two small ileocolic veins. The abdomen was then closed with catgut. 5, 12,4 Another PE-50 catheter was placed in the femoral artery for mean arterial pressure (MAP) measurement and drug infusion. Both catheters were capped, tunnelled under the skin, and were brought out onto the surface of the midback. The animals were placed in standard polyethylene cages and allowed to awaken fully for 4h before the measurements. The catheters were then connected to pressure transducers (Nihon Kohden AP-641G, Tokyo, Japan) with the zero reference set at the rat's midthoracic level. The rectal temperature was maintained at 37~176 with heating lamps throughout the experiment. Diltiazem was infused for 1 min at doses of 300, 600, or 1200 ~g/kg body weight (bw). Nicardipine was infused for 1rain at doses of 15, 30, or 60~tg/kgbw. Control rats were infused with saline lml per 100gbw. Portal pressure and MAP were recorded before and at 5, 10, 15, 30, and 60rain after infusion.
Hemodynarnic studies
With the animal under ether anesthesia, a catheter was introduced into the left ventricle via the right carotid artery for radioactive microsphere injection. Correct positioning of the catheter was confirmed by pressure tracing as previously described. 1>17 A catheter was inserted into the femoral artery to monitor MAP, infuse drugs, and to withdraw the reference blood sample. Both catheters were tunnelled under the skin and brought out onto the surface of the midback. The rats were then placed in polyethylene cages and allowed to wake up and recover unrestrained for 4h before the blood flow studies were conducted. During the experiments, heating lamps were used to warm the rats.
Liver blood flow studies
Liver blood flow was measured using sTCo-labeled microspheres 15 ~tm in diameter (NEN-TRAC Microspheres, DuPont, Boston, MA, USA) as previously described, t>~7 The microspheres were mixed, diluted, and drawn up into polyethylene tubing for counting in a gamma counter (Aroka ARC-221, Tokyo, Japan) before injection. The microspheres were injected into the left ventricle over a period of 20s. Starting 10s before the microsphere injection, a reference blood sample was withdrawn from the femoral artery catheter using a withdrawal pump (Sage Instruments syringe pump model 351, Boston, Mass.) at a rate of lml/min for 1.5rain. Immediately after blood flow measurements, portosystemic shunting was measured as previously described, la13 Briefly, under ether anesthesia, the spleen was exposed through a laparotomy and 85Sr-labeled microspheres were injected over 20s. The rats were then killed and the individual organs dissected. The radioactivity in each organ and in the reference blood samples was determined. Adequate mixing of the microspheres was assumed when the difference of radioactivity between the left and right kidney was less than 10%. Diltiazem was infused over 1rain via the femoraI artery in the above doses and hemodynamic studies were performed 5min after the infusion. Nicardipine was infused over lmin in the above doses and hemodynamic studies were performed 10rain after the infusion.
Portal pressure and regional blood flows were not measured in the same rat since laparotomy with insertion of a portal vein catheter may change splanchnic blood flow? 8
Calculations
Cardiac output (CO) was calculated by the following formula: CO(ml/min) = injected radioactivity (cpm) • reference sample withdrawal rate (ml/min)/reference blood radioactivity (cpm).
The cardiac index (CI) was derived from the following formula: CI(ml/min per kg bw) = CO/kg bw.
Regional blood flow was calculated according to the following formula: organ blood flow (ml/min) = organ radioactivity (cpm) • CO/radioactivity injected (cpm).
Portal tributary blood flow (PTBF) was taken as the sum of blood flow to the spleen, stomach, small intestine, large intestine, mesentery, and pancreas and represents the total blood flow entering into the portal venous system. Hepatic arterial blood flow was expressed as the organ blood flow of the liver. Organ blood flow as expressed as ml/kg per rain.
Portosysternic shunting (PSS) was calculated using the following formula: PSS (%) = [lung 85Sr radioactivity (cpm) /(liver + lung) 8sSr radioactivity (cpm)] • 100.
Systemic vascular resistance (SVR) was calculated
according to the following formula: SVR (mmHg.min/ ml) = MAP (mmHg)/CO (ml/min).
Portal tributary vascular resistance (PTVR) was calculated as: PTVR (mmHg.min/ml) = [MAP (mmHg) -PP(mmHg)]/PTBF (ml/min). Portal pressure was a mean value determined separately in the sham-operated and portal vein-ligated (PVL) rat.
Combined hepatic and collateral vascular resistance
(hepatocollateral vascular resistance) was calculated as: portal pressure (mmHg)/PTBF (ml/min) using mean portal pressure and the individual PTBF.
This calculation assumed that central venous pressure is zero.
Statistical analysis
Results are expressed as mean _+ S.E. The differences between the control and the treatment groups were assessed by analysis of variance (ANOVA) with Dunnett's multiple comparison and paired Student's t-test. A P value of less than 0.05 was considered as statistically significant.
Results
Mean arterial pressure (MAP) and portal pressure (PP) responses
MAP and PP responses to diltiazem and nicardipine are shown in Figs. 1 and 2 . Under basal conditions, PP was significantly higher in PVL rats than in sham-operated rats: 15.8 + 0.4 and 10.2 _+ 0.4mmHg (P < 0.01). MAP was significantly lower in PVL rats than in shamoperated rats: 113.4 -+ 1.5 and 120.2 + 2.0mmHg (P < 0.01). MAP and PP were not different in each of the groups of PVL rats, nor in each of the groups of sham-operated rats. Saline infusion had no effect on MAP and PP. Five minutes after diltiazem and nicardipine infusion, MAP decreased significantly in both the PVL and sham-operated rats, and returned to baseline after 60rain. The PP did not change in the sham-operated groups nor in the PVL groups.
Systemic and splanchnic hemodynamics
The results of systemic and splanchnic hemodynamic responses to diltiazem and nicardipine are given Tables  1, 2 , and 3. Five minutes after diltiazem administration 
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T +7.8%; 600gg: +27.6% (P < 0.05); 1200~g: +15.7%. Nicardipine 15~tg: +35.9% (P < 0.05); 30~tg: +49.4% (P < 0.01); 60~g: +44.1% (P < 0.01)]. This increase was mainly due to a significant elevation in blood flow to the small intestine and mesentery (Table 3) . Portal tributary blood flow was not changed by these doses of diltiazem or nicardipine in sham-operated rats.
Portosystemic shunting (PSS)
In sham-operated rats. PSS was less than 0.1%. In PV!, rats, PSS was 54.7 + 6.1% and was not different in any of the groups. The degree of shunting was not affected by diltiazem and nicardipine (data not shown).
Systemic and splanchnic vascular resistance
The results of systemic and splanchnic vascular resistance are shown in Tables 4 and 5 . When compared with PVL rats and sham-operated rats in saline-infused groups, hepatocollateral vascular resistance was significantly higher in PVL rats than in sham-operated rats: 1.49 + 0.12 and 0.91 _+ 0.098mmHg min/ml (P < 0.01). Systemic vascular resistance and portal tributary vascular resistance were not different between the two groups. After administration of diltiazem and nicardipine, portal tributary vascular resistance was decreased in both PVL and sham-operated rats. This change was greatest with nicardipine infusion in PVL rats [15~,g: -40.8% (P < 0.01); 30btg: -59.7% (P < 0.01); 60~,g: -50.6% (P < 0.01)]. Hepatocollateral vascular resistance was significantly decreased in PVL rats [Diltiazem 300[,g: -24.5% (P < 0.05); 600btg:
21.4% (P < 0.05); 1200btg: -20.1%. Nicardipine 15[,g: -16.7%; 30~g: -41.3% (P < 0.01); 60~,g: -25.4% (P < 0.05)]. This change was not seen in sham-operated rats.
Discussion
Theoretically, there are two possible ways to lower portal pressure, namely, through a reduction in liver blood flow or through a reduction in the portal vascular resistance. Pharmacotherapy of portal hypertension has been limited so far to lowering portal pressure by decreasing splanchnic blood flow. a941 Decreasing perfusion of an organ with an already compromised blood flow and function, however, could lead to a further decrease in function. Since hepatic perfusion is a major determinant of hepatic function, it would appear more desirable to lower portal pressure by reducing the resistance to hepatic perfusion.
Several compounds have been shown to reduce resistance of the cirrhotic organ. The most clear-cut results have been obtained in perfused livers of rats rendered cirrhotic by long-term administration of CC14. 8 The calcium antagonist verapamil induced a significant lowering of portal resistance. Nevertheless, in several studies in alcoholic patients, verapamil had no effect on hepatic hemodynamics? 1-23 Diltiazem and nicardipine are two other calcium antagonists that are known to be more potent vasodilators. Furthermore, unlike verapamil, they have little propensity to induce direct bradycardia or atrioventricular blockade in the usual therapeutic doses? It was the purpose of the present study to investigate the hemodynamic effects of diltiazem and nicardipine in an experimental model of portal hypertension. Partial portal vein ligation (PVL) in the rat is a commonly used model of portal hypertension. Several of the hemodynamic features of this model are similar to those seen in chronic liver disease.4.6.H,~2,~4
In the present study, we demonstrated that in PVL rats, portal tributary blood flow increased after the injection of diltiazem and nicardipine. This increase was not accompanied by an increase in the cardiac index. The decrease of portal tributary vascular resistance was greater than that of systemic vascular resistance, suggesting a partially selective effect on the splanchnic vasculature. It has been previously reported in normal rats that diltiazem and nicardipine administration in rather high doses increased portal venous inflow. 24 It is not clear why portal tributary blood flow increased at lower doses in PVL rats. In PVL rats, liver function is not disturbed, so the pharmacokinetics would not be expected to be modified. It is possible that the vascular responses to calcium antagonists are changed in these animals or in portal hypertension.
Our study further suggests that the marked changes in portal tributary blood flow with minimal changes in portal pressure seen in PVL rats are the result of an alteration of hepatocollateral vascular resistance. In the normal rat, portal venous resistance represents primarily intrahepatic resistance to portal blood flow, since collaterals are practically nonexistent. In the portal hypertensive model, the resistance offered to portal venous flow has two components, a resistance produced by the ligature constricting the portal vein and a variable resistance created by the portal-systemic collaterals. The extrahepatic collateral circulation that develops as a consequence of the portal hypertensive process becomes a major site influencing the vascular responses of the portal system in portal hypertension. However, the effects of vasoactive drugs on portal collateral circulation are not clearY Some reports have demonstrated that propranolol increased the combined hepatic and collateral vascular resistance, so the reduction in portal pressure was minimal despite the marked decrease in portal tributary blood flow. 14, 26, 27 In experimental studies, mosidomine, a long-acting vasodilator, decreased portal pressure by reducing collateral vascular resistance by more than 30%. 2a On the other hand, Oberti et al. reported that venous dilatation of collateral vessels did not decrease portal pressure . 29 The effects of calcium antagonist on portal collateral resistance are not well defined. 3~ Karaki and Weiss have reported that calcium channel blockers affect all smooth muscle cells examined? ~ Ohmiya demonstrated that isolated veins, including the portal vein, showed regional differences in responsiveness to calcium blockers. Diltiazem and nicardipine were found to inhibit portal vein constriction markedly by adrenalin. 32 In the present in vivo experimental study, these drug~ were found to decrease the hepatocollateral resistance in PVL rats. The elevation in portal pressure was therefore prevented despite the marked increase in portal tributary blood flow.
Since calcium antagonists do not decrease portal pressure in portal hypertensive rats, their efficacy in the treatment of portal hypertension is questionable. However, calcium antagonists increase portal blood flow without increase of portal pressure. Thus, they may be suitable for the treatment of hypertension in patients with liver cirrhosis. But in the present study, since we did not measure collateral blood flow directly, an excess increase of portal blood flow might worsen esophageal varices. The use of calcium antagonists would be restricted to patients without severe portal hypertension.
In conclusion, diltiazem and nicardipine demonstrate selective vasodilatory effects on the splanchnic circulation. The portal pressure does not increase in parallel with the increase in portal tributary blood flow because of the decrease in portocollateral vascular resistance. Further pharmacological studies, however, are needed to delineate the mechanisms involved in the present findings.
